NCT04795882: MCARTY

A New Study Evaluating the Activity of Modular CAR T for mYeloma

Recruiting now Phase 1 Last updated 20 November 2025

What this trial tests

Phase 1 trial testing BCMA CAR T cells in Multiple Myeloma in 27 participants. Currently enrolling.

Timeline

22 April 2022

Primary endpoint
31 March 2029

31 March 2029

Quick facts

Lead sponsor	University College, London
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	22 April 2022
Primary completion	31 March 2029
Estimated completion	31 March 2029
Sites	1 location across United Kingdom

Drugs / interventions tested

• BCMA CAR T cells
• BCMA/CD19 CAR T cells — full drug profile →

Conditions studied

• Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

University College, London

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1 rolling 6 trial design evaluating safety of a novel BCMA Chimeric Antigen Receptor (CAR) alone and of CAR T cells engineered to co-express BCMA CAR and a CD19 CAR in patients with relapsed / refractory Multiple Myeloma.

The study will assess the feasibility of generating these Advanced Therapy Investigational Products (ATIMPs) and the safety of administering the CAR T cells (either BCMA alone or co-expressed with CD19) in patients with relapsed / refractory multiple myeloma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
   Kegyes D, Constantinescu C, Vrancken L, Rasche L, et al · · 2022 · cited 53× · PMID 35672793 · DOI 10.1186/s13045-022-01296-2
2. Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.
   Cho SF, Xing L, Anderson KC, Tai YT. · · 2021 · cited 28× · PMID 34885245 · DOI 10.3390/cancers13236136
3. AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival.
   Mehra V, Agliardi G, Dias Alves Pinto J, Shafat MS, et al · · 2023 · cited 22× · PMID 37709295 · DOI 10.1136/jitc-2023-007002
4. Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment.
   Ho M, Xiao A, Yi D, Zanwar S, et al · · 2022 · cited 20× · PMID 36421358 · DOI 10.3390/curroncol29110705
5. Chimeric antigen receptor T-cell therapy for multiple myeloma.
   Wang Z, Chen C, Wang L, Jia Y, et al · · 2022 · cited 12× · PMID 36618390 · DOI 10.3389/fimmu.2022.1050522
6. Updates on CAR T cell therapy in multiple myeloma.
   Nasiri F, Asaadi Y, Mirzadeh F, Abdolahi S, et al · · 2024 · cited 10× · PMID 39261906 · DOI 10.1186/s40364-024-00634-5
7. Multi-targeted immunotherapeutics to treat B cell malignancies.
   Gambles MT, Yang J, Kopeček J. · · 2023 · cited 8× · PMID 37121515 · DOI 10.1016/j.jconrel.2023.04.048
8. Rediscovering hemostasis abnormalities in multiple myeloma: The new era.
   Huang Y, Wang C, Wang H, Liu H, et al · · 2024 · PMID 39055831 · DOI 10.1016/j.heliyon.2024.e34111